Gould IM, Bal AM. New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence. 2013;4:185-191.
Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed June 23, 2018.
Kong KF, Schneper L, Mathee K. Beta-lactam antibiotics: from antibiosis to resistance and bacteriology. APMIS. 2010;118:1-36.
Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54:969-976.
Ambler RP. The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci. 1980;289:321-331.
Cornaglia G, Giamarellou H, Rossolini GM. Metallo-beta-lactamases: a last frontier for beta-lactams? Lancet Infect Dis. 2011;11:381-393.
Davido B, Fellous L, Lawrence C, et al. Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome beta-lactam resistance conferred by metallo-beta-lactamases in enterobacteriaceae and pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017;61.
Lomovskaya O, Sun D, Rubio-Aparicio D, et al. Vaborbactam: Spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in enterobacteriaceae. Antimicrob Agents Chemother. 2017;61.
Evans BA, Amyes SG. OXA beta-lactamases. Clin Microbiol Rev. 2014;27:241-263.
Vasoo S, Barreto JN, Tosh PK. Emerging issues in gram-negative bacterial resistance: an update for the practicing clinician. Mayo Clin Proc. 2015;90:395-403.
Martirosov DM, Lodise TP. Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae. Diagn Microbiol Infect Dis. 2016;85:266-275.
van Duin D, Kaye KS, Neuner EA, et al. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013;75:115-120.
Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55:943-950.
Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect. 2011;17:1135-1141.
Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin/beta-lactamase inhibitor combination. Drugs. 2013;73:159-177.
Zasowski EJ, Rybak JM, Rybak MJ. The beta-lactams strike back: ceftazidime-avibactam. Pharmacotherapy. 2015;35:755-770.
Sader HS, Castanheira M, Duncan LR, et al. Antimicrobial susceptibility of enterobacteriaceae and pseudomonas aeruginosa isolates from United States medical centers stratified by infection type: results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015-2016. Diagn Microbiol Infect Dis. 2018. doi: 10.1016/j.diagmicrobio.2018.04.012. [Epub ahead of print].
Avycaz^® [package insert]. Irvine, California: Allergan USA, Inc.; 2018.
Torres A, Rank D, Rekeda L, et al. Phase 3, randomized, double-blind noninferiority study of ceftazidime–avibactam vs. meropenem in the treatment of patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia: analyses of the REPROVE study per US FDA endpoints. Open Forum Infectious Diseases. 2017;4:S535-S535.
Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: Results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis. 2016;62:1380-1389.
Wagenlehner FM, Sobel JD, Newell P, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis. 2016;63:754-762.
Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16:661-673.
van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis. 2018;66:163-171.
Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61.
Haidar G, Clancy CJ, Shields RK, et al. Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 2017;61.
Zhanel GG, Lawrence CK, Adam H, et al. Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-beta-lactamase inhibitor combinations. Drugs. 2018;78:65-98.
Pfaller MA, Huband MD, Mendes RE, et al. In vitro activity of meropenem-vaborbactam and characterization of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem-vaborbactam surveillance program. Int J Antimicrob Agents. 2018. doi: 10.1016/j.ijantimicag.2018.02.021. [Epub ahead of print].
Castanheira M, Rhomberg PR, Flamm RK, et al. Effect of the beta-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2016;60:5454-5458.
Vabomere^® [package insert]. Lincolshire, Illinois: Melinta Therapeutics, Inc.; 2018.
Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018;319:788-799.
Kaye KS, Vasquez J, Mathers A, et al. Meropenem-vaborbactam vs. best available therapy for CRE infections: TANGO II randomized, controlled phase 3 study results. Poster presented at: IDWeek 2017; October 4-8, 2017; San Diego, California. Poster 1862.
Karaiskos I, Souli M, Giamarellou H. Plazomicin: an investigational therapy for the treatment of urinary tract infections. Expert Opin Investig Drugs. 2015;24:1501-1511.
Castanheira M, Streit JM, Arends SJR, et al. Activity of plazomicin and comparator agents tested against contemporary clinical isolates collected worldwide. Poster presented at: 2018 American Society for Microbiology Annual Meeting; June 7-11, 2018; Atlanta, Georgia. Poster 645.
Doi Y, Wachino JI, Arakawa Y. Aminoglycoside resistance: the emergence of acquired 16S ribosomal RNA methyltransferases. Infect Dis Clin North Am. 2016;30:523-537.
Zemdri^® [package insert]. South San Francisco, California: Achaogen, Inc.; 2018.
Cloutier D, Miller L, Komirenko A, et al. Evaluating once-daily plazomicin versus meropenem for the treatment of complicated urinary tract infection and acute pyelonephritis: results from a phase 3 study (EPIC). Presented at: 2017 American Society of Microbiology Annual Meeting; June 1-5, 2017; New Orleans, Louisiana. Session 437.
Cloutier D, Komirenko A, Cebrik D, et al. Plazomicin vs. meropenem for complicated urinary tract infection and acute pyelonephritis: diagnosis-specific results from the phase 3 EPIC study. Open Forum Infectious Diseases. 2017;4:S532-S532.
Golan Y, Cloutier D, Komirenko A, et al. Improved outcomes at late follow-up with plazomicin compared with meropenem in patients with complicated urinary tract infection or acute pyelonephritis in the EPIC study. Open Forum Infectious Diseases. 2017;4:S533-S534.
Connelly L, Jubb AM, O'Keeffe B. Plazomicin is associated with improved survival and safety compared to colistin in serious carbapenem-resistant Enterobacteriaceae infections: results of the CARE study. Presented at: 2017 American Society of Microbiology Annual Meeting; June 1-5, 2017; New Orleans, Louisiana. Session 264.
Blizzard TA, Chen H, Kim S, et al. Discovery of MK-7655, a beta-lactamase inhibitor for combination with Primaxin(R). Bioorg Med Chem Lett. 2014;24:780-785.
Lob SH, Hackel MA, Kazmierczak KM, et al. In vitro activity of imipenem-relebactam against gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (results from the SMART global surveillance program). Antimicrob Agents Chemother. 2017;61: e02209-16.
Sims M, Mariyanovski V, McLeroth P, et al. Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother. 2017;72:2616-2626.
Lucasti C, Vasile L, Sandesc D, et al. Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother. 2016;60:6234-6243.
Motsch J, De Oliveira C, Stus V, et al. RESTORE-IMI 1: A multicenter, randomized, double-blind, comparator-controlled trial comparing the efficacy and safety of imipenem/relebactam versus colistin plus imipenem in patients with imipenem-non-susceptible bacterial infections. Presented at: 28th European Congress of Clinical Microbiology and Infectious Diseases; April 21-24, 2018; Madrid, Spain. Abstract O0427.
Zhanel GG, Cheung D, Adam H, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016;76:567-588.
Xiao XY, Hunt DK, Zhou J, et al. Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. J Med Chem. 2012;55:597-605.
Zhanel GG, Baxter MR, Adam HJ, et al. In vitro activity of eravacycline against 2213 gram-negative and 2424 gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015. Diagn Microbiol Infect Dis. 2018;91:55-62.
Livermore DM, Mushtaq S, Warner M, et al. In vitro activity of eravacycline against carbapenem-resistant enterobacteriaceae and acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60:3840-3844.
Abdallah M, Olafisoye O, Cortes C, et al. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother. 2015;59:1802-1805.
Solomkin J, Evans D, Slepavicius A, et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg. 2017;152:224-232.
Horn P, Tsai L, Solomkin P, et al. Results of IGNITE4: a phase-3 study to evaluate the efficacy and safety of eravacycline versus meropenem in complicated intra-abdominal infections. Presented at: 28th European Congress of Clinical Microbiology and Infectious Diseases; April 21-24, 2018; Madrid, Spain. Abstract O0421.
Tetraphase Pharmaceuticals. (2015). Tetraphase announces top-line results from IGNITE2 phase 3 clinical trial of eravacycline in cUTI [press release]. Retrieved from http://ir.tphase.com/static-files/ce14dbec-014f-42d4-9f00-90a308226e7d. Accessed June 21, 2018.
Tetraphase Pharmaceuticals. (2018). Tetraphase announces top-line results from IGNITE3 phase 3 clinical trial of eravacycline in complicated urinary tract infections (cUTI) [press release]. Retrieved from http://ir.tphase.com/node/9821/pdf. Accessed June 21, 2018.
Choi JJ, McCarthy MW. Cefiderocol: a novel siderophore cephalosporin. Expert Opin Investig Drugs. 2018;27:193-197.
Hackel MA, Tsuji M, Yamano Y, et al. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 study). Antimicrob Agents Chemother. 2017;61.
Ito-Horiyama T, Ishii Y, Ito A, et al. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother. 2016;60:4384-4386.
Tillotson GS. Trojan horse antibiotics-a novel way to circumvent gram-negative bacterial resistance? Infect Dis (Auckl). 2016;9:45-52.
Ito A, Nishikawa T, Matsumoto S, et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60:7396-7401.
Portsmouth S, Van Veenhuyzen D, Echols R, et al. Clinical response of cefiderocol compared with imipenem/cilastatin in the treatment of adults with complicated urinary tract infections with or without pyelonephritis or acute uncomplicated pyelonephritis: Results from a multicenter, double-blind, randomized study (APEKS-cUTI). Open Forum Infectious Diseases. 2017;4:S537-S538.
Silver LL. Fosfomycin: mechanism and resistance. Cold Spring Harb Perspect Med. 2017;7.
Kaye KS, Rice LB, Dane A, et al. Intravenous fosfomycin (ZTI-01) for the treatment of complicated urinary tract infections including acute pyelonephritis: results from a multi-center, randomized, double-blind phase 2/3 study in hospitalized adults (ZEUS). Open Forum Infectious Diseases. 2017;4:S528-S528.
Centers for Disease Control and Prevention. Core Elements of Hospital Antibiotic Stewardship Programs. https://www.cdc.gov/antibiotic-use/healthcare/implementation/core-elements.html. Accessed June 23, 2018.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Monique R. Bidell, PharmD, BCPS

Assistant Professor of Pharmacy Practice
Albany College of Pharmacy and Health Sciences
Albany, New York

Disclosures

Disclosure: Monique R. Bidell, PharmD, BCPS, has disclosed no relevant financial relationships.

Dr Bidell does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Bidell does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Thomas P. Lodise

Professor
Albany College of Pharmacy and Health Sciences
Albany, New York

Disclosures

Disclosure: Thomas P. Lodise, PharmD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Achaogen, Inc.; Allergan, Inc.; Melinta Therapeutics, Inc.; Shoingai; Zavante Therapeutics, Inc.
Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Melinta Therapeutics, Inc.

Dr Lodise does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Lodise does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editors

Susan L. Smith, MN, PhD

Lead Scientific Director, Medscape, LLC

Disclosures

Disclosure: Susan L. Smith, MN, PhD, has disclosed no relevant financial relationships.

Shira Berman

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Shira Berman has disclosed no relevant financial relationships.

Megan Whitney, DMD

Medical Writer, Sandy Hook, Connecticut

Disclosures

Disclosure: Megan Whitney, DMD, has disclosed no relevant financial relationships.

CME Reviewer(s)

Esther Nyarko, PharmD

Associate CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC / CE

Time to Evolve: Addressing the Challenge of Carbapenem-Resistant Enterobacteriaceae

Authors: Thomas P. Lodise, PharmD, PhD; Monique R. Bidell, PharmD, BCPS
CME / ABIM MOC / CE Released: 6/26/2018
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 6/26/2019, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for ID/HIV specialists, critical care specialists, urologists, and pharmacists.

The goals of this activity are to increase awareness of the public health threat of multidrug-resistant infections (especially carbapenem-resistant Enterobacteriaceae [CRE]), new and emerging antibiotics to treat these infections, and the importance of antibiotic stewardship in their use.

Upon completion of this activity, participants will have increased knowledge regarding the

Key distinguishing characteristics of new and emerging antibiotics for the treatment of CRE infection
Potential benefits of newer antimicrobial agents against CRE infection

Disclosures

Faculty

Monique R. Bidell, PharmD, BCPS

Assistant Professor of Pharmacy Practice
Albany College of Pharmacy and Health Sciences
Albany, New York

Disclosures

Disclosure: Monique R. Bidell, PharmD, BCPS, has disclosed no relevant financial relationships.

Dr Bidell does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Bidell does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Thomas P. Lodise

Professor
Albany College of Pharmacy and Health Sciences
Albany, New York

Disclosures

Disclosure: Thomas P. Lodise, PharmD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Achaogen, Inc.; Allergan, Inc.; Melinta Therapeutics, Inc.; Shoingai; Zavante Therapeutics, Inc.
Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Melinta Therapeutics, Inc.

Dr Lodise does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Lodise does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editors

Susan L. Smith, MN, PhD

Lead Scientific Director, Medscape, LLC

Disclosures

Disclosure: Susan L. Smith, MN, PhD, has disclosed no relevant financial relationships.

Shira Berman

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Shira Berman has disclosed no relevant financial relationships.

Megan Whitney, DMD

Medical Writer, Sandy Hook, Connecticut

Disclosures

Disclosure: Megan Whitney, DMD, has disclosed no relevant financial relationships.

CME Reviewer(s)

Esther Nyarko, PharmD

Associate CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Pharmacists

Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-18-130-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Infectious Diseases

CME / ABIM MOC / CE

Time to Evolve: Addressing the Challenge of Carbapenem-Resistant Enterobacteriaceae

Authors: Thomas P. Lodise, PharmD, PhD; Monique R. Bidell, PharmD, BCPSFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 6/26/2018

Valid for credit through: 6/26/2019, 11:59 PM EST

processing....

Abbreviations

AE = adverse event
AmpC = AmpC beta-lactamases
AP = acute pyelonephritis
BSI = bloodstream infection
CDC = Centers for Disease Control and Protection
CI = confidence interval
cIAI = complicated intra-abdominal infection
CrCl = creatinine clearance
CRACKLE = Consortium on Resistance Against Carbapenems in Klebsiella and other Enterobacteriaceae
CRE = carbapenem-resistant Enterobacteriaceae
cUTI = complicated urinary tract infection
ESBL = extended spectrum β-lactamase
ESKAPE = Enterococcus faecium, Staphylococcus aureus, K. pneumoniae, A. baumannii, P. aeruginosa, and Enterobacter spp
FDA = US Food and Drug Administration
GNB = Gram-negative bacteria
HABP = hospital-acquired bacterial pneumonia
INFORM = International Network for Optimal Resistance Monitoring
IPM/CS = imipenem/cilastatin
IV = intravenous
KPC = Klebsiella pneumoniae carbapenemase
MBL = metallo-β-lactamase
MDR = multidrug-resistant
MDR-GNB = multidrug-resistant gram-negative bacteria
MDRO = multidrug-resistant organism
MIC = minimal inhibitory concentration
NDM = New Delhi metallo-β-lactamase
OXA-48 = carbapenem-hydrolysing class D β-lactamases
PBP = protein-binding site
PK = pharmacokinetic
rRNA = ribosomal RNA
VABP = ventilator-associated bacterial pneumonia

« Return to: Time to Evolve: Addressing the Challenge of Carbapenem-Resistant Enterobacteriaceae

CME / ABIM MOC / CE Information

Print
Like Tweet

References

Faculty and Disclosures

Faculty

Monique R. Bidell, PharmD, BCPS

Thomas P. Lodise

Editors

Susan L. Smith, MN, PhD

Shira Berman

Megan Whitney, DMD

CME Reviewer(s)

Esther Nyarko, PharmD

Peer Reviewer

CME / ABIM MOC / CE

Time to Evolve: Addressing the Challenge of Carbapenem-Resistant Enterobacteriaceae

Target Audience and Goal Statement

Disclosures

Faculty

Monique R. Bidell, PharmD, BCPS

Thomas P. Lodise

Editors

Susan L. Smith, MN, PhD

Shira Berman

Megan Whitney, DMD

CME Reviewer(s)

Esther Nyarko, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

For Pharmacists

Instructions for Participation and Credit

Time to Evolve: Addressing the Challenge of Carbapenem-Resistant Enterobacteriaceae

Abbreviations